Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 11/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310284 | 0.88 | MAP4K1 (0.37) | MAP4K1HRH4TNK2BRD4 | |
| SCHEMBL24309583 | 0.85 | DYRK1A (0.35) | MAP4K1HRH4TNK2EGLN1TTK | |
| SCHEMBL24309240 | 0.84 | ALDH1A1 (0.36) | MAP4K1EGLN1BRD4JAK2JAK3 | |
| SCHEMBL29566640 | 0.84 | ALDH1A1 (0.36) | MAP4K1EGLN1BRD4JAK2JAK3 | |
| SCHEMBL24309872 | 0.83 | CCNA2 (0.40) | BRD4 | |
| SCHEMBL24309954 | 0.82 | HTR1D (0.36) | MAP4K1HRH4 | |
| SCHEMBL24310533 | 0.82 | MAP4K1 (0.35) | MAP4K1HRH4 | |
| SCHEMBL24309556 | 0.81 | MAP4K1 (0.35) | MAP4K1BRD4JAK2JAK3 | |
| SCHEMBL24310347 | 0.81 | GPR39 (0.39) | TNK2 | |
| SCHEMBL24309518 | 0.80 | LMNA (0.39) | MAP4K1BRD4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |